Blockbusters propel Sanofi-Synthelabo
Reporting first-quarter 2001 consolidated sales of 1.55 billion euros($1.38 billion), Sanofi-Synthelabo says that developed sales (global sales generated with marketing partners Bristol-Myers Squibb and Pharmacia) recorded very strong growth, particularly in the USA.
Developed sales of the platelet antiaggregant Plavix/ Iscover (clopidogrel) rose 54% on a comparable basis to 429 million euros (Sanofi's own turnover rising 83% to 180 million euros); those of the hypnotic Stilnox/ Ambien/Myslee (zolpidem) rocketed 91% to 278 million euros (+55% to 146 million euros for Sanofi); and the antihypertensive Aprovel/Avapro/Karvea (irbesartan) increased 40% to 202 million euros (+56% to 94 million euros) in the quarter.
On a geographic basis, Sanofi reported a 55% rise in US sales to 250 million euros on a comparable basis, while turnover in France was up a modest 3% at 348 million euros. European sales (excluding France) rose 11% to 561 million euros, those in Japan were up 13% at 87 million euros and the rest of the world contributed 248 million euros, up 26% on the like, 2000 quarter.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze